The World Health Organisation (WHO) has declared 2026 a pivotal year for turning political promises into concrete action to end major epidemics. This call comes after a challenging 2025, which saw significant disruptions in global health funding.
A Year of Challenge and Resilience
In a message to partners, Dr Tereza Kasaeva, WHO Director of the Department for HIV, TB, Hepatitis & STIs, described 2025 as a difficult period. It was marked by unprecedented disruption following cuts in official development assistance for health. Despite this constrained environment, Dr Kasaeva noted that countries and communities demonstrated remarkable resilience by rebuilding and adapting.
She emphasised that the WHO remained steadfast, providing strategic leadership and critical tools to member states. Throughout the year, the organisation developed global guidelines, monitored epidemic trends, and delivered technical support to strengthen national responses, particularly for key and vulnerable populations.
Key Breakthroughs and Global Momentum in 2025
Dr Kasaeva highlighted several critical advancements achieved in 2025. A major milestone was WHO's approval of twice-yearly injectable lenacapavir for HIV prevention. This long-acting alternative to daily oral PrEP is seen as transformative, especially for individuals facing barriers like stigma or adherence issues.
In the fight against Tuberculosis (TB), the WHO accelerated progress by supporting rapid diagnostics and shorter treatment regimens. The TB Vaccine Accelerator Council also released a landmark report during the G20 Health Ministers’ Meeting, advocating for innovative financing to ensure equitable access to new TB vaccines for adolescents and adults.
Significant strides were made under the triple elimination agenda. The Maldives became the first country to eliminate mother-to-child transmission of HIV, syphilis, and hepatitis B. Botswana advanced to gold-tier status for eliminating vertical HIV transmission, and Brazil was validated for ending mother-to-child HIV transmission.
However, challenges persist. New data from the Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) underscored the growing threat of drug-resistant gonorrhoea, highlighting an urgent need for better surveillance and access to effective treatments.
The Path Forward for 2026
Dr Kasaeva stated that 2026 will be critical for translating political momentum into bold, decisive action. The goal is to accelerate progress toward global targets and ensure equitable access to high-quality, people-centred services for everyone, regardless of their location or identity.
She paid special tribute to frontline health workers, survivors, communities, and donors, whose dedication has been instrumental. Dr Kasaeva concluded by asserting that through continued collaboration, innovation, and determination, the global community can overcome these epidemics and build a healthier, fairer world.
